Highlights•AAV is a non-pathogenic virus, and recombinant AAV vectors have proven to be
highly efficient for gene delivery to a wide variety of cell types, tissue, and organs in small …

Glioblastoma (GBM) is the most common and malignant Grade IV primary craniocerebral
tumor caused by glial cell carcinogenesis with an extremely poor median survival of 12–18 …

Effective gene delivery to the central nervous system (CNS) is vital for development of novel
gene therapies for neurological diseases. Adeno-associated virus (AAV) vectors have …

Recently, we described a modified AAV2 vector—AAV2‐7m8—having a capsid‐displayed
peptide insertion of 10 amino acids with enhanced retinal transduction properties. The …

Adeno-associated virus rhesus isolate 8 (AAVrh. 8) is a leading vector for the treatment of
neurological diseases due to its efficient transduction of neuronal cells and reduced …

Adeno-associated virus (AAV) has provided the gene therapy field with the most powerful in
vivo gene delivery vector to realize safe, efficacious, and sustainable therapeutic gene …

The adeno-associated viruses (AAV) are promising therapeutic gene delivery vectors and
better understanding of their capsid assembly and genome packaging mechanism is …

Adeno-associated virus (AAV) vectors can mediate long-term expression of immunogenic
transgenes in vivo through transduction of tolerogenic cells in the liver. Tissue-targeted AAV …

The invention provides compositions and methods for the preparation, manufacture and
therapeutic use of viral vectors, such as adeno-associated virus (AAV) particles having viral …

Adeno-associated viruses utilize different glycans and the AAV receptor (AAVR) for cellular
attachment and entry. Directed evolution has yielded new AAV variants; however, structure …